Compare Stocks → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:NVIVOTCMKTS:NVTRQNASDAQ:SINTOTCMKTS:TEAROTCMKTS:VLRXQ Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsNVTRQNuvectra$0.02-25.0%$0.02$0.01▼$4.30N/AN/AN/A382,600 shsSINTSintx Technologies$0.04$0.09$0.02▼$1.82$812K1.4721.89 million shs33.39 million shsTEARTearLab$0.06-1.9%$0.06$0.02▼$0.22N/AN/AN/A20,200 shsVLRXQValeritas$0.02$0.02$0.01▼$4.28N/AN/AN/AN/A7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVIVInVivo Therapeutics0.00%0.00%0.00%-52.32%-75.89%NVTRQNuvectra0.00%0.00%0.00%0.00%0.00%SINTSintx Technologies-5.79%+56.33%-61.30%-88.66%-97.82%TEARTearLab0.00%0.00%0.00%0.00%0.00%VLRXQValeritas0.00%0.00%0.00%0.00%0.00%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVTRQNuvectraN/AN/AN/AN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ATEARTearLabN/AN/AN/AN/AN/AN/AN/AN/AVLRXQValeritasN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVIVInVivo TherapeuticsN/AN/AN/AN/ANVTRQNuvectraN/AN/AN/AN/ASINTSintx Technologies2.00HoldN/AN/ATEARTearLabN/AN/AN/AN/AVLRXQValeritasN/AN/AN/AN/ACurrent Analyst RatingsLatest NVIV, SINT, TEAR, NVTRQ, and VLRXQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/5/2024SINTSintx TechnologiesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ANVTRQNuvectraN/AN/AN/AN/AN/AN/ASINTSintx Technologies$2.63M0.31N/AN/A$1.65 per share0.02TEARTearLabN/AN/AN/AN/AN/AN/AVLRXQValeritasN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ANVTRQNuvectraN/AN/A0.00∞N/AN/AN/AN/AN/ASINTSintx Technologies-$8.26M-$3.42N/A∞N/A-314.39%-67.12%-45.49%5/20/2024 (Estimated)TEARTearLabN/AN/A0.00∞N/AN/AN/AN/AN/AVLRXQValeritasN/AN/A0.00∞N/AN/AN/AN/AN/ALatest NVIV, SINT, TEAR, NVTRQ, and VLRXQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023SINTSintx TechnologiesN/A-$0.09-$0.09-$0.09N/A$0.90 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVIVInVivo TherapeuticsN/AN/AN/AN/AN/ANVTRQNuvectraN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ATEARTearLabN/AN/AN/AN/AN/AVLRXQValeritasN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVIVInVivo TherapeuticsN/A14.3014.30NVTRQNuvectraN/AN/AN/ASINTSintx TechnologiesN/A1.901.60TEARTearLabN/AN/AN/AVLRXQValeritasN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVIVInVivo Therapeutics13.78%NVTRQNuvectraN/ASINTSintx Technologies18.38%TEARTearLabN/AVLRXQValeritasN/AInsider OwnershipCompanyInsider OwnershipNVIVInVivo Therapeutics2.45%NVTRQNuvectra2.90%SINTSintx Technologies0.79%TEARTearLab5.20%VLRXQValeritas1.02%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableNVTRQNuvectra197N/AN/ANot OptionableSINTSintx Technologies4122.68 million22.50 millionNot OptionableTEARTearLab34N/AN/ANot OptionableVLRXQValeritas125N/AN/ANot OptionableNVIV, SINT, TEAR, NVTRQ, and VLRXQ HeadlinesSourceHeadlineIndividualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetesmedscape.com - February 15 at 2:26 PMValeritas Holdings Inc (VLRXQ)investing.com - June 20 at 10:41 PMVaccines Delivery Devices Market – A Comprehensive Study by Key ... - StreetBuzznews.google.com - May 14 at 1:36 AMMicroneedle Drug Delivery Systems Market Incredible Possibilities ... - StreetBuzznews.google.com - May 13 at 12:25 AMMicroneedle-based Drug Delivery System Market – A ... - StreetBuzznews.google.com - May 12 at 2:25 PMLiquid-based Needle-Free Injector Market Scope, Trends, Growth ... - Taiwan Newsnews.google.com - May 12 at 2:25 PMDiabetes Devices Market Business Strategies and Massive Demand ... - Cottonwood Holladay Journalnews.google.com - May 11 at 8:22 AMWearable Injectors Market Research & Advancements by 2028 ... - Cottonwood Holladay Journalnews.google.com - May 11 at 8:22 AMDiabetes Devices Market Size, Trends, Share, Growth and Forecast ... - Cottonwood Holladay Journalnews.google.com - May 11 at 8:22 AMMedical Insulin Pumps Market 2023 – Top Manufacturers, Latest ... - Cottonwood Holladay Journalnews.google.com - May 11 at 8:22 AMInfusion Pump Market Estimated to Reach USD 27.03 Billion by ... - Digital Journalnews.google.com - May 11 at 8:22 AMInsulin Pump Market Estimated to Reach USD 18.15 Billion by 2030 ... - Digital Journalnews.google.com - May 11 at 8:22 AMIntramuscular Injector Market To Witness Huge Growth by 2030 | Edmund Healthcare, BD, Injex Pharma - openPRnews.google.com - May 10 at 10:20 PMInsulin Pump Market Growth, Analysis & Forecast to 2032 ... - Cottonwood Holladay Journalnews.google.com - May 10 at 10:20 PMNeedle-Free Drug Delivery Devices Market | Exclusive Report on ... - Cottonwood Holladay Journalnews.google.com - May 10 at 10:20 PMInsulin Delivery Pump Market 2023 Global analysis, opportunities ... - Taiwan Newsnews.google.com - May 10 at 7:18 AMDisposable Insulin-Delivery Device Market Size 2022 to 2032 | By ... - Future Market Insightsnews.google.com - May 9 at 6:01 AMGlobal Smart Insulin Pens and Pumps Market to Reach $8.3 Billion by 2030 - Yahoo Financenews.google.com - May 8 at 3:00 PMGlobal Intramuscular Injector Market Size 2023, Growth Prospects ... - The Northwestern Examinernews.google.com - May 8 at 3:00 PMGlobal Smart Insulin Pens and Pumps Market to Reach $8.3 Billion ... - GlobeNewswirenews.google.com - May 8 at 9:59 AMInsulin Pump Accessories Market 2031 Insights with Key Innovations ... - Fylladeynews.google.com - May 7 at 9:25 AMTubeless Insulin Pump Market Research Report 2023-2031 to ... - The Northwestern Examinernews.google.com - May 7 at 4:24 AMOn-Body Injectors Market to Witness Comprehensive Growth 2023-2030| BD Medical, Medtronic, Insulet - openPRnews.google.com - May 7 at 4:24 AMMicroneedle Drug Delivery Systems Market: Opportunities ... - Digital Journalnews.google.com - May 4 at 4:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsInVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.NuvectraOTCMKTS:NVTRQNuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.Sintx TechnologiesNASDAQ:SINTSintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.TearLabOTCMKTS:TEARTearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.ValeritasOTCMKTS:VLRXQValeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.